Conveners
Data-driven mechanistic cancer models: Part A
- Susan Massey (Mayo Clinic)
Data-driven mechanistic cancer models: Part B
- Susan Massey (Mayo Clinic)
Description
In recent years, there has been an explosion of multiscale cancer patient data including genomic, metabolomic, proteomic, and histologic (with novel stainings), at the tissue scale and smaller, along with a host of advanced MRI and other clinical imaging sequences at the whole organ scale. While bountiful, the multiscale and spatial sparsity represented with these data types for any individual patient leaves the final interpretation difficult with traditional statistical methods. Mechanistic models provide a framework for exploring how these processes interlink and contribute to tumour growth and evolution. Incorporating this multitude of data into such models remains a challenging and open problem, however, promising results are emerging. The talks in this minisymposium will highlight novel models and approaches to using these new data types in exploring the mechanisms underlying cancer growth and response to therapy.
It is well known that growth and survival of cancer stem cells (CSCs) is highly influenced by tumour microenvironmental factors and molecular signalling, initiated by cytokines and growth factors. IL-6 is a key regulator of a number of cellular processes including proliferation, survival, differentiation, migration and invasion and it is also commonly overexpressed in many cancers. Recent...
Mathematical modelling of the stochastic evolutionary process of carcinogenesis can be used to derive and to optimize the timing of clinical screens so that the probability is maximal that an individual is screened within a certain "window of opportunity" for intervention when early cancer development may be observed. By using data from epidemiological studies with long-term patient follow-up,...
Glioblastoma Multiforme (GBM) is the most aggressive primary brain tumour, with a median life expectancy of only 15 months with treatment. Although surgical resection is a standard-of-care procedure, the migratory nature of the tumour cells limits its efficacy as not all tumour cells can be removed. The tumour will usually re-establish itself along the resection cavity wall, known as a local...
Glioblastoma multiforme (GBM) is a rare brain cancer with a median survival of only around 15 months. Intratumoural heterogeneity and extensive infiltration into the brain tissue contribute to poor prognosis and probable recurrence. Predicting the timing of post-treatment recurrence is often limited if using only MRI imaging measurements, as a diverse range of treatment outcomes can result...
Introduction: Glioblastoma (GBM) is a very aggressive primary brain cancer, noted for its diffuse infiltration into surrounding normal–appearing brain. This particular nature makes GBM notoriously difficult to treat, as these diffusely invading cells cannot be resected surgically, are difficult to target with radiation therapy, and thus must be targeted with chemotherapy. However, this too...